Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level.
about
Profile of verteporfin and its potential for the treatment of central serous chorioretinopathyAdvances in the treatment of central serous chorioretinopathyOne-year results of reduced fluence photodynamic therapy for central serous chorioretinopathy: the outer nuclear layer thickness is associated with visual prognosis.Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot studyHalf-dose verteporfin combined with half-fluence photodynamic therapy for chronic central serous chorioretinopathy.Intravitreal anti-vascular endothelial growth factor versus observation in acute central serous chorioretinopathy: one-year results.Meta-analysis of best corrected visual acuity after treatment for myopic choroidal neovascularisation.[Therapy options for chronic central serous chorioretinopathy. Photodynamic therapy combined with bevacizumab - a case series].Oscillatory photodynamic therapy for choroidal neovascularization and central serous retinopathy; a pilot study.Diagnosis and interventions for central serous chorioretinopathy: review and update.Long-term results of half-dose photodynamic therapy for chronic central serous chorioretinopathy with contrast sensitivity changes.The effect of photodynamic therapy on macular sensitivity in eyes with acute central serous chorioretinopathy.Choroidal thickness outside the laser irradiation area after photodynamic therapy in polypoidal choroidal vasculopathy.Central serous chorioretinopathy: update on pathophysiology and treatment.Effects of smoking on visual acuity of central serous chorioretinopathy patients.Responsiveness of eyes with polypoidal choroidal vasculopathy with choroidal hyperpermeability to intravitreal ranibizumab.Half-fluence photodynamic therapy to treat chronic central serous chorioretinopathy: A case series.The chorioretinal damage caused by different half parameters of photodynamic therapy in rabbits.System review and meta-analysis on photodynamic therapy in central serous chorioretinopathy.Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy.Short-term efficacy of subthreshold micropulse yellow laser (577-nm) photocoagulation for chronic central serous chorioretinopathy.Evaluation of central serous retinopathy with en face optical coherence tomography.Comparing half-dose photodynamic therapy with high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy (the PLACE trial): study protocol for a randomized controlled trial.Photodynamic therapy and anti-vascular endothelial growth factor for acute central serous chorioretinopathy: a systematic review and meta-analysis.Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol.Intravitreal bevacizumab for treatment of refractory central serous choroidoretinopathyPhotodynamic therapy: current role in the treatment of chorioretinal conditionsHalf-dose vs one-third-dose photodynamic therapy for chronic central serous chorioretinopathy.Comparison of subthreshold micropulse laser (577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathyLow-Fluence Photodynamic Therapy versus Subthreshold Micropulse Yellow Wavelength Laser in the Treatment of Chronic Central Serous Chorioretinopathy.Structural and Functional Outcomes in Chronic Central Serous Chorioretinopathy Treated with Photodynamic Therapy.Changes in Choroidal Structures in Eyes with Chronic Central Serous Chorioretinopathy after Half-Dose Photodynamic TherapyMultiple spots of photodynamic therapy for the treatment of severe chronic central serous chorioretinopathy.A Review of Subthreshold Micropulse Laser for Treatment of Macular DisordersLong-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).Association of Choroidal Neovascularization and Central Serous Chorioretinopathy With Optical Coherence Tomography Angiography.Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy.Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.Effects of photodynamic therapy with verteporfin for the treatment of chronic central serous chorioretinopathy: An uncontrolled, open-label, observational studyLack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review.
P2860
Q26824756-46F8D18C-536E-44CF-8CEA-5C5F97CBF580Q28088443-EE3E7A92-820E-4665-8E00-63412BA223DDQ31112014-04FBBD13-AEA7-40A4-BEE8-33693F33502EQ33239033-AAA584E6-E958-489C-833D-87D6A82882BEQ33705962-52EF2E92-953E-402D-9A0E-3EB1EC990D2CQ33996055-14F749C3-996A-4A0D-883E-6AA3050B3733Q34063100-543C1294-7010-41DA-B6F4-27DF7E474401Q34076295-0449767C-9E79-4917-B26C-1D9A4FC21535Q34210541-1145810F-07ED-4487-9A91-514731C461AEQ34334335-7311C5D1-9C10-47F4-871F-EC46A5790D7DQ34334673-484192AA-DD03-4249-9C43-8D5A054D3494Q34394791-57831B5B-87EB-42B0-880C-7097FC3F468DQ34585510-0C7C6A68-94A8-4B4E-939C-75626BDB3724Q34587658-D60C0184-29BD-45F7-A812-C5186B49EEE9Q34809984-B99D094F-E9AB-46B3-A348-516400ADB3E2Q34958682-F4E579B8-AD3B-4185-B16C-1BDE0CF82267Q35176611-779730D0-E9AF-4E62-B370-69ED0B6E1A53Q35192101-20424119-1EA1-49CB-B903-84B91039D67DQ35209632-DFF9EE5D-5D0C-457F-82AC-D85BF5B242E5Q35561222-BB401C7B-9E14-4E45-9A06-382D54D796E6Q35567966-BF19EF23-08E5-4B69-A689-6D6EC2D4EC29Q35593954-A8A23A05-3867-4F44-BBDB-788B9BA1F2BFQ35782233-17270FCF-AC79-40F7-896A-13CB32129E67Q35826493-7FC02FF9-6E7B-4A1B-8E20-EB85D5AC5C0EQ35869490-721C424A-F903-4148-8F32-1CEE1ADCB949Q35886959-E4E46BFA-FFA9-4E32-9494-49B0E68FB561Q35888341-D262E536-6292-453A-97D3-30FC091619D8Q35955614-D2171450-8B72-4C59-878F-75059E143295Q36071607-719EAF8B-515A-4CB8-BEAA-E1F9293DCCD0Q36123646-636D043C-B5AB-4623-BF4F-C9EFEB715754Q36127289-514BA509-6050-4FCE-812C-E84BFAB45B5FQ36135515-692948CF-76E7-4B21-AD6D-10D4EE2B060BQ36326807-2B05AD5B-8496-446D-8A47-125C7566EC97Q36379671-571E42EF-B946-4F15-B1DC-1C51FF947F93Q36407625-893555A0-52A5-4F7C-B167-40B3900C3877Q36487164-ED1DE2EE-FE85-4BFD-952C-E3B809E8F71BQ36685488-27D82BE4-04E5-4234-A5F6-8724CA643D64Q36883236-3F57F1D2-884E-4DE0-A9FE-FD2494E76855Q37667426-7B375432-FE3C-48DB-8B42-4630A83BEBC7Q38160720-D0A13D0F-D59D-4526-AB19-146338D0BB4E
P2860
Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level.
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Choroidal vascular remodelling ...... at the primary disease level.
@ast
Choroidal vascular remodelling ...... at the primary disease level.
@en
type
label
Choroidal vascular remodelling ...... at the primary disease level.
@ast
Choroidal vascular remodelling ...... at the primary disease level.
@en
prefLabel
Choroidal vascular remodelling ...... at the primary disease level.
@ast
Choroidal vascular remodelling ...... at the primary disease level.
@en
P2093
P2860
P356
P1476
Choroidal vascular remodelling ...... at the primary disease level.
@en
P2093
P2860
P304
P356
10.1136/BJO.87.12.1453
P407
P577
2003-12-01T00:00:00Z